Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model.
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
Identification of shared genes and pathways: a comparative study of multiple sclerosis susceptibility, severity and response to interferon Beta treatment.
Self-Reported Fatigue and Energy Cost During Walking Are Not Related in Patients With Multiple Sclerosis.
MSer – A new, neutral descriptor for someone with multiple sclerosis
Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis.
Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler's murine encephalomyelitis virus-induced demyelinating disease.
Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models.
France Banned AB Science Drug Studies Because of Side Effects
A pilot randomised controlled trial of an Internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue.
[Chronic cerebrospinal venous insufficiency--pathophysiology and treament].
Granzyme B-Induced Neurotoxicity Is Mediated via Activation of PAR-1 Receptor and Kv1.3 Channel.
Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment.
The genetics of multiple sclerosis: an up-to-date review.
Substance Name: Phenytoin
Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells.
Added benefit of fampridine is not proven
MRI characteristics of familial and sporadic multiple sclerosis patients.
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Shifting imaging targets in multiple sclerosis: From inflammation to neurodegeneration.
The spectrum of MOG autoantibody-associated demyelinating diseases.
Exome sequencing in single cells from the cerebrospinal fluid in multiple sclerosis.
Is natalizumab overshooting its rebound?
Suppression of Experimental Autoimmune Optic Neuritis by the Novel Agent Fingolimod.
Modulation of alertness by sustained cognitive demand in MS as surrogate measure of fatigue and fatigability.

Pages